As of December 2024, out of a total of 1,226 patients that received an iPSC (-derived) therapy worldwide, 320 patients received Cynata's iPSC-MSCs as part of one of our clinical trials:
In case you are wondering, that makes if around 1 in 4 patients worldwide - and that doesn't even include or ongoing P2 trial in HR-aGvHD.
As of December 2024, only one P3 trial worldwide - SCULptTOR, using Cynata's iPSC-MSCs. That trial also happens to be fully recruited and has been since November 2023, with final data collection taking place in November 2025 and read-outs expected in early 2026.
Of course though, these people publishing papers on platforms other than HC know nothing. Unless they receive a 100+ thumbs up on HC, please, take their research with a grain of salt, or two.
CYP Price at posting:
26.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)